1-5 of 5
Urszula M. Polanska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

Free
James T. Lynch, Urszula M. Polanska, Ursula Hancox, Oona Delpuech, Juliana Maynard, Catherine Trigwell, Catherine Eberlein, Carol Lenaghan, Radoslaw Polanski, Alvaro Avivar-Valderas, Marie Cumberbatch, Teresa Klinowska, Susan E. Critchlow, Francisco Cruzalegui, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (11): 2309–2319.
https://doi.org/10.1158/1535-7163.MCT-18-0183
Published: 02 November 2018
View article titled, Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
Open the PDF for Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors in another window
Includes: Supplementary data
Journal Articles

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Free
Chrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, Oona Delpuech, Jon O. Curwen, Larissa S. Carnevalli, Anna D. Staniszewska, Urszula M. Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S. Carroll, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 908–920.
https://doi.org/10.1158/1535-7163.MCT-17-0537
Published: 30 April 2018
View article titled, Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
Open the PDF for Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Free
Kevin Hudson, Urs J. Hancox, Cath Trigwell, Robert McEwen, Urszula M. Polanska, Myria Nikolaou, Pablo Morentin Gutierrez, Alvaro Avivar-Valderas, Oona Delpuech, Phillippa Dudley, Lyndsey Hanson, Rebecca Ellston, Alys Jones, Marie Cumberbatch, Sabina C. Cosulich, Lara Ward, Francisco Cruzalegui, Stephen Green
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 877–889.
https://doi.org/10.1158/1535-7163.MCT-15-0687
Published: 05 May 2016
View article titled, Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Open the PDF for Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers in another window
Includes: Supplementary data
Journal Articles

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Free
Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D'Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2508–2518.
https://doi.org/10.1158/1535-7163.MCT-15-0365
Published: 03 November 2015
View article titled, AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Open the PDF for AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules in another window
Includes: Supplementary data
Journal Articles

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Free
Ricardo Ribas, Sunil Pancholi, Stephanie K. Guest, Elisabetta Marangoni, Qiong Gao, Aurélie Thuleau, Nikiana Simigdala, Urszula M. Polanska, Hayley Campbell, Aradhana Rani, Gianmaria Liccardi, Stephen Johnston, Barry R. Davies, Mitch Dowsett, Lesley-Ann Martin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (9): 2035–2048.
https://doi.org/10.1158/1535-7163.MCT-15-0143
Published: 02 September 2015
View article titled, AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Open the PDF for AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo in another window
Includes: Supplementary data